Bayer challenges cancer drug ruling favouring Natco

Patents office had allowed Natco to sell cheaper generic version of German firm's drug Nexavar

Drugmaker has said that it is challenging an order from the patents office that allowed Hyderabad-based Pharma to sell a cheap generic version of the German firm's drug in India. Nexavar is used in the treatment of of the kidney and liver.

The patents office had stripped Bayer of its exclusive rights to sell Nexavar, saying most Indians could not afford it.

It told Natco Pharma to sell the generic drug significantly more cheaply and pay Bayer a 6% royalty on sales.

Bayer said it had appealed against the ruling.

"We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.

India's decision on Nexavar was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.

Separately, Bayer is suing another Indian drugmaker, Cipla, for patent infringement over Nexavar. has been selling generic Nexavar in India and it has slashed the price of the drug by 75% to Rs 6,840 a month.

image
Business Standard
177 22
Business Standard

Bayer challenges cancer drug ruling favouring Natco

Patents office had allowed Natco to sell cheaper generic version of German firm's drug Nexavar

Reuters 



Drugmaker has said that it is challenging an order from the patents office that allowed Hyderabad-based Pharma to sell a cheap generic version of the German firm's drug in India. Nexavar is used in the treatment of of the kidney and liver.

The patents office had stripped Bayer of its exclusive rights to sell Nexavar, saying most Indians could not afford it.

It told Natco Pharma to sell the generic drug significantly more cheaply and pay Bayer a 6% royalty on sales.

Bayer said it had appealed against the ruling.

"We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.

India's decision on Nexavar was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.



Separately, Bayer is suing another Indian drugmaker, Cipla, for patent infringement over Nexavar. has been selling generic Nexavar in India and it has slashed the price of the drug by 75% to Rs 6,840 a month.

RECOMMENDED FOR YOU

Bayer challenges cancer drug ruling favouring Natco

Patents office had allowed Natco to sell cheaper generic version of German firm's drug Nexavar

Drugmaker Bayer has said that it is challenging an order from the patents office that allowed Hyderabad-based Natco Pharma to sell a cheap generic version of the German firm's drug Nexavar in India. Nexavar is used in the treatment of cancer of the kidney and liver.

Drugmaker has said that it is challenging an order from the patents office that allowed Hyderabad-based Pharma to sell a cheap generic version of the German firm's drug in India. Nexavar is used in the treatment of of the kidney and liver.

The patents office had stripped Bayer of its exclusive rights to sell Nexavar, saying most Indians could not afford it.

It told Natco Pharma to sell the generic drug significantly more cheaply and pay Bayer a 6% royalty on sales.

Bayer said it had appealed against the ruling.

"We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.

India's decision on Nexavar was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.

Separately, Bayer is suing another Indian drugmaker, Cipla, for patent infringement over Nexavar. has been selling generic Nexavar in India and it has slashed the price of the drug by 75% to Rs 6,840 a month.

image
Business Standard
177 22
Widgets Magazine

More News

  • Vishal Sikka Infosys to give clearer picture on guidance post Q2
  • Gammon Infra shares down nearly 5% after Q1 results Gammon Infra shares down nearly 5% after Q1 results
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard